RxDoctor Payments Data

Adnan Said, MD

Hepatology · Madison, WINPI 1669433454

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $136,535 of the $156,426 with a category attached, or 87.3%. 7 manufacturers reported payments, led by Mallinckrodt Hospital Products Inc. at 50.3% of the total. 2025 is the largest year on record at $71,680, more than ten times the $2,884 reported in 2019.

$156,426in general payments, 2019–2025

Across 99 payments — averaging $1580.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mallinckrodt Hospital Products Inc.$79K
  • Madrigal Pharmaceuticals$37K
  • Novo Nordisk$36K
  • Gilead$3K
  • Intercept Pharmaceuticals, Inc.$2K
  • Lantheus Medical Imaging, Inc.$350
  • plus $120 from 1 others
$148,587in research payments, 2019–2025

Across 39 payments — averaging $3809.93 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Intercept Pharmaceuticals, Inc.$119K
  • Intercept Pharma Europe Ltd.$20K
  • Boehringer Ingelheim International GmbH$9K

What the payments were for

  • Consulting fees$11,7257%
  • Speaking & faculty fees$136,53587%
  • Travel & lodging$5,5144%
  • Food & beverage$2,5872%
  • Education$650%

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few hepatology providers in Wisconsinto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$16,507
Medicare patients
108
Services billed
377

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin36$114,039
Envarsus XrTacrolimus33$23,667
Mycophenolic AcidMycophenolate Sodium92$22,559
Everolimus13$22,092
Ursodiol172$19,753
Tacrolimus225$14,408
Sirolimus37$6,365
Mycophenolate Mofetil46$2,530
Azathioprine27$1,338
Pantoprazole Sodium55$715
Entecavir19$645
Prednisone125$611
Hydroxyzine Hcl12$389
Carvedilol45$227
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim22$186

Paid to pharmacies, not to this prescriber.

Other hepatology in Madison

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →